Evidence map›Paper›PMID 36268506›Full record

ArticleFrontiers in cell and developmental biology2022

Improved contractile potential in detrusor microtissues from pediatric patients with end stage lower urinary tract dysfunction.

Tim Gerwinn, Souzan Salemi, Larissa J Schori, Dafni Planta, Daniel Eberli, Maya Horst

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tim GerwinnDivision of Pediatric Urology, University Children's Hospital Zurich, Zurich, Switzerland.
Souzan SalemiLaboratory for Urologic Oncology and Stem Cell Therapy, Department of Urology, University Hospital Zurich, Zurich, Switzerland.
Larissa J SchoriLaboratory for Urologic Oncology and Stem Cell Therapy, Department of Urology, University Hospital Zurich, Zurich, Switzerland.
Dafni PlantaDivision of Pediatric Urology, University Children's Hospital Zurich, Zurich, Switzerland.
Daniel EberliLaboratory for Urologic Oncology and Stem Cell Therapy, Department of Urology, University Hospital Zurich, Zurich, Switzerland.
Maya HorstDivision of Pediatric Urology, University Children's Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous cell-based tissue engineering has been proposed as a treatment option for end stage lower urinary tract dysfunction (ESLUTD). However, it is generally accepted that cells isolated from patient bladders retain the pathological properties of their tissue of origin and therefore need to be improved before they can serve as a cell source for tissue engineering applications. We hypothesize that human three-dimensional (3D) microtissues of detrusor smooth muscle cells (SMCs) are valuable

Indexed as

bladderextracellular matrixlower urinary tract dysfunctionneurogenicpediatricsmooth musclespheroid

Identifiers

PMID36268506
PMCPMC9577217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.